"Two birds with one stone"——The role of sulfonylureas in the treatment of "periodontitis-diabetes" comorbidity

Periodontitis is one of the most common oral inflammatory diseases, mainly affecting the periodontal tissue by affecting the host immune system and bone homeostasis.

Since bacterial imbalance is the main cause of periodontitis, antibiotics are widely used clinically to treat periodontitis, but the effect is not satisfactory

Sulfonylureas are the earliest and most widely used oral hypoglycemic agents for the treatment of type 2 diabetes

The main cause of alveolar bone loss in periodontitis is an imbalance of bone metabolism, mainly due to the increased number and activity of osteoclasts

In a rat periodontitis model, oral administration of glyburide significantly inhibited the infiltration of inflammatory cells and osteoclasts in periodontal tissue

Effects of sulfonylureas on bone metabolism and vascular function

Sulfonylureas stimulate pancreatic beta cells to increase insulin secretion, a bone anabolic factor that acts through insulin receptor substrate (IRS) signaling and glucose uptake

In conclusion, sulfonylureas have multiple therapeutic potentials beyond the traditional treatment of diabetes

Periodontitis, diabetes, and periodontitis-diabetic comorbidities affect a variety of local and systemic functions, and sulfonylureas have shown potential to mitigate these effects

The above studies have shown that sulfonylureas may have therapeutic effects by directly acting on periodontitis, suggesting that they may be used alone in the treatment of periodontitis

References: 1.

2.